GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NVN Liquidation Inc (LTS:0A4P) » Definitions » Loans Receivable

NVN Liquidation (LTS:0A4P) Loans Receivable : $0.00 Mil (As of Mar. 2023)


View and export this data going back to 2020. Start your Free Trial

What is NVN Liquidation Loans Receivable?

NVN Liquidation's Loans Receivable for the quarter that ended in Mar. 2023 was $0.00 Mil.


NVN Liquidation Loans Receivable Historical Data

The historical data trend for NVN Liquidation's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NVN Liquidation Loans Receivable Chart

NVN Liquidation Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Loans Receivable
Get a 7-Day Free Trial Premium Member Only - - - - -

NVN Liquidation Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NVN Liquidation Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


NVN Liquidation Loans Receivable Related Terms

Thank you for viewing the detailed overview of NVN Liquidation's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


NVN Liquidation Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 64, Pittsboro, NC, USA, 27312
NVN Liquidation Inc Formerly Novan Inc is a dermatology company focused on developing and commercializing therapeutic products for skin diseases. It is developing SB206 as a topical prescription gel for the treatment of viral skin infections. The company's product portfolio includes; Wynzora Cream for the treatment of plaque psoriasis, Rhofade cream for the treatment of persistent facial erythema, Minolira tablets to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients, Cloderm cream for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Sitavig tablets for the treatment of recurrent herpes labialis in immunocompetent adults, and Nuvail nail solution for managing signs and symptoms of nail dystrophy.

NVN Liquidation Headlines

No Headlines